Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

This study has been terminated.

First Received: April 17, 2007 Last Updated: August 23, 2007 History of Changes

Sponsor:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00463762

Purpose

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Condition	Intervention	Phase
Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis	Drug: CP-75385-02 Cefoperazone/sulbactam	Phase IV

Study Type:	Observational
Study Design:	Natural History, Cross-Sectional, Defined Population, Prospective Study
Official Title:	Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Resource links provided by NLM:

MedlinePlus related topics: Appendicitis

Drug Information available for: Cefoperazone Cefoperazone sodium Sulbactam Sulbactam sodium

U.S. FDA Resources

Further study details as provided by Pfizer:

Estimated Enrollment:	200
Study Start Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patient of age 18 years or older.
Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00463762

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	A1891004
Study First Received:	April 17, 2007
Last Updated:	August 23, 2007
ClinicalTrials.gov Identifier:	NCT00463762 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Gallbladder Diseases
Communicable Diseases
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Disorders of Environmental Origin
Infection
Anti-Bacterial Agents
Acalculous Cholecystitis
Appendicitis
Biliary Tract Diseases
Therapeutic Uses
Peritoneal Diseases
Suppuration

Wound Infection
Abdominal Abscess
Cefoperazone
Peritonitis
Wounds and Injuries
Cholecystitis
Enzyme Inhibitors
Intestinal Diseases
Pharmacologic Actions
Cecal Diseases
Sulbactam
Digestive System Diseases
Abscess
Gastroenteritis

ClinicalTrials.gov processed this record on November 30, 2009